Guardian Pharmacy Services (GRDN) Projected to Post Quarterly Earnings on Monday

Key Points

• Guardian Pharmacy Services is set to announce its Q2 2025 earnings on Monday, August 11th, with analysts expecting earnings of $0.22 per share and revenue of $329.57 million.
• The company's stock recently traded up 0.4%, reaching $20.41, with an average trading volume well below normal.
• Analysts have upgraded Guardian Pharmacy Services to a "buy" rating with a target price of $28.00, indicating a positive outlook for the company's future performance.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of $0.22 per share and revenue of $329.57 million for the quarter.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.01). The business had revenue of $329.31 million during the quarter, compared to analyst estimates of $321.21 million. On average, analysts expect Guardian Pharmacy Services to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Guardian Pharmacy Services Stock Performance

Guardian Pharmacy Services stock traded down $0.56 during trading hours on Friday, hitting $19.92. 136,048 shares of the stock traded hands, compared to its average volume of 118,117. The firm's 50-day moving average price is $20.59 and its two-hundred day moving average price is $21.46. Guardian Pharmacy Services has a one year low of $14.16 and a one year high of $26.91.

Analysts Set New Price Targets

GRDN has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Guardian Pharmacy Services from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Raymond James Financial set a $28.00 price objective on shares of Guardian Pharmacy Services and gave the stock an "outperform" rating in a report on Wednesday, May 14th. Finally, Truist Financial restated a "buy" rating and issued a $28.00 price objective (up from $25.00) on shares of Guardian Pharmacy Services in a report on Monday, May 19th.

Insider Transactions at Guardian Pharmacy Services

In other news, Director Thomas J. Salentine, Jr. sold 3,508,905 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total value of $70,739,524.80. Following the transaction, the director directly owned 2,591,271 shares in the company, valued at $52,240,023.36. This trade represents a 57.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director William E. Bindley sold 3,508,905 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total value of $70,739,524.80. Following the completion of the transaction, the director owned 2,591,271 shares in the company, valued at approximately $52,240,023.36. This trade represents a 57.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,344,912 shares of company stock worth $228,713,426. Company insiders own 63.71% of the company's stock.

Institutional Investors Weigh In On Guardian Pharmacy Services

A hedge fund recently bought a new stake in Guardian Pharmacy Services stock. Dynamic Technology Lab Private Ltd acquired a new position in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,975 shares of the company's stock, valued at approximately $233,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.